Showing 5841-5850 of 6035 results for "".
- Oculus Announces New Joystick for the Keratograph 5M With Release Functionhttps://modernod.com/news/oculus-announces-new-joystick-for-the-keratograph-5m-with-release-function/2479779/As of September 2018, the Oculus Keratograph 5M comes equipped with a new joystick including a release function. This enables the user to capture images and video sequences with the simple push of a button on the devi
- Aura Biosciences to Present Phase 1b/2 Clinical Data for AU-011 at AAOhttps://modernod.com/news/aura-biosciences-to-present-phase-1b-2-clinical-data-for-au-011-at-aao/2479786/Aura Biosciences announced that it will be highlighting its phase 1b/2 clinical data for AU-011, the company’s lead product candidate for the primary treatment of choroidal melanoma, in two oral presentations at the American Academy of Ophthalmology (AAO) 2018 Annual Meeting being held October 27
- EyePoint Pharmaceuticals Receives FDA Approval of Yutiq for Chronic Noninfectious Uveitishttps://modernod.com/news/eyepoint-pharmaceuticals-receives-fda-approval-of-yutiq-for-noninfectious-uveitis/2479787/EyePoint Pharmaceuticals announced that the FDA has approved Yutiq (fluocinolone acetonide intravitreal implant) for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye. Yutiq utilizes the company’s Durasert drug delivery technology and is a non-bioerodible i
- Falls in Elders May Be Driving Up Secondary Diagnoses of Eye Traumahttps://modernod.com/news/falls-in-elders-may-be-driving-up-secondary-diagnoses-of-eye-trauma/2479788/Hospital admissions due to eye trauma have declined since 2001, but more and more patients are being admitted with a secondary diagnosis of eye trauma, largely due to an increase in falls among older people, new findings suggest, according to a Reuters
- IGF1-Targeting Teprotumumab Tackles Thyroid Eye Diseasehttps://modernod.com/news/igf1-targeting-teprotumumab-tackles-thyroid-eye-disease/2479794/Patients with moderate to severe thyroid-associated ophthalmopathy show significant improvements with treatment with teprotumumab (River Vision Development) extending as far out as 72 weeks, according to a report in Medscape. ̶
- Konan Medical USA Acquires objectiveFIELD Objective Perimeterhttps://modernod.com/news/konan-medical-usa-acquires-objectivefield-objective-perimeter/2479795/Konan Medical USA has acquired objectiveFIELD, an FDA-cleared device designed to assess the human visual field in an objective and non-contact manner. The device was acquired from the Australian National University (ANU), includes novel features licensed from Seeing Machine
- Sensimed Announces Approval of the Sensimed Triggerfish in Japanhttps://modernod.com/news/sensimed-announces-approval-of-the-sensimed-triggerfish-in-japan/2479800/Sensimed has announced the registration of the Sensimed Triggerfish sensor and monitoring system as a medical device in Japan. The Japanese partner and distributor of Sensimed, SEED Co., h
- Vision Ophthalmology Group Acquires MED Medical Products GmbHhttps://modernod.com/news/vision-ophthalmology-group-acquires-med-medical-products-gmbh/2479803/Vision Ophthalmology Group (VOG) has announced the acquisition of MED Medical Products, effective immediately. Terms of the deal were not disclosed. Karlstein, Germany-based MED is a specialist producer of customized procedure packs and disposable products used in ophthalmic surgery
- Silgan Dispensing Introduces Iridya Eye Dropper to Ensure Accurate Doses Down to the Drophttps://modernod.com/news/silgan-dispensing-introduces-iridya-eye-dropper-to-ensure-accurate-doses-down-to-the-drop/2479804/Silgan Dispensing has launched Iridya, a next-generation, multi-dose preservative-free eye dropper. The Iridya eye dropper ensures consumers an accurate dose and an easy-to-use design, while also providing safe delivery of ophthalmic medication. Its elongated tip provides greater accuracy when di
- High Dose of Sildenafil Tied to Long-term Retinal Damage in Case Reporthttps://modernod.com/news/high-dose-of-sildenafil-tied-to-long-term-retinal-damage-in-case-report/2479814/A patient who took a high dose of the erectile dysfunction drug sildenafil citrate developed long-term, and possibly irreversible, retinal damage with bilateral multicolored photopsia (perceived flashes of light) and erythropsia (red-tinted vision), according to a